Key Highlights

  • Aurora Cannabis (NASDAQ:ACB) agreed on November 2, 2026 to be acquired by Organigram for an elective CAD 7.80 in cash per share, or 5.8626 Organigram shares, or a cash and share mix.
  • The offer carries a 93% premium to the August 10, 2026 unaffected price and is 21% above the implied value of Curaleaf's hostile bid, with Equity value near CAD 561 million fully diluted.
  • Proration caps limit consideration to 205,826,172 Organigram shares and CAD 253,638,772 in cash in total, so each holder's final mix may differ from the election.
  • Shareholder meetings are expected in December 2026, and closing is expected in January 2027 after court, TSX and regulatory approvals, including German clearance.

The Terms and the Competing Bid

The arrangement agreement, signed on November 2, 2026 and announced on November 3, lets each Aurora Cannabis (NASDAQ:ACB) holder elect CAD 7.80 in cash, 5.8626 Organigram shares, or CAD 3.75 in cash plus 3.0431 Organigram shares, subject to proration. Both boards approved it unanimously, and Aurora's board rejected the hostile bid from Curaleaf. Published coverage says Curaleaf has kept its bid open after the Organigram deal. The premium of 93% is measured against the August 10, 2026 price, before the contest began, so a Market Price above that level is expected. Organigram's chief executive called the transaction a defining step in building a disciplined, global cannabis leader.

Financing and Conditions

Organigram (NASDAQ:OGI) plans a private Placement with BAT of 141.0 million shares, stated as 100 million pounds, about CAD 187.5 million, plus an ATB Credit Facility of up to CAD 210 million. The release's per-share price for the placement is inconsistent, so it is omitted here. BAT, which holds about 30% of Organigram votes, signed an irrevocable voting agreement. Aurora needs two-thirds of votes cast plus a majority of the minority under MI 61-101, and Organigram needs a simple majority excluding BAT. A British Columbia court, the TSX and regulators must also approve. Fairness opinions came from BMO, Fort Capital and Origin Merchant Partners. The special meetings are expected in December 2026, and the arrangement is a court-approved plan under British Columbia corporate law.

Risks and What to Watch

The main risks are a higher or revised Curaleaf offer, proration that leaves holders with a different mix than they chose, a failed vote and the exposure that comes with taking Organigram stock, whose value moves with the combined company's performance. Published market data showed Aurora shares up about 22%. The break fee was not disclosed in the release. Cannabis equities can be volatile, and a small number of trades can move quotes. Investors in Aurora Cannabis (NASDAQ:ACB) should read the circular, which will detail the election mechanics and the special meeting date. Curaleaf has not withdrawn, so a higher bid remains possible, though none is announced. Holders who prefer certainty may favour cash, while those who want upside in the combined company may elect shares.

Where Things Stand

Aurora Cannabis (NASDAQ:ACB) holders can cash in only if the arrangement is approved, and a 93% premium to the unaffected price is a strong headline, but the contest with Curaleaf's hostile bid is not over. The Organigram offer is 21% above the implied value of that bid and has board support and a key shareholder's backing. Watch the December meetings, any revised Curaleaf proposal and the proration outcome before treating the premium as locked in. Cash elections are capped, so not every holder will receive all cash.